Drug intelligence / Profile preview

dronabinol + cannabidiol

Development stage: Unknown
Lead developer: University of California, San Diego
Modality: Small Molecules
Administration: Oral

Overview

This investigation refers to the study of the cannabinoids dronabinol and cannabidiol (CBD) by the University of California, San Diego (UCSD), specifically for their acute effects on patients with bipolar disorder. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC) that acts as a partial agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2), mimicking the psychoactive and therapeutic effects of natural cannabis. Cannabidiol is a non-intoxicating cannabinoid with a complex pharmacological profile, acting as a negative allosteric modulator of CB1 and an agonist at the 5-HT1A receptor. The UCSD clinical program (NCT02432313) utilized a randomized, double-blind, placebo-controlled crossover design to evaluate how these substances influence cognitive performance and circulating endocannabinoid levels in individuals with bipolar disorder compared to healthy volunteers.

Brand names: MarinolEpidiolex
Other names: THC + CBDdelta-9-tetrahydrocannabinol + cannabidiolCannabis in Bipolar Disorder and Healthy Volunteers study drugs

Targets

CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPV1 (Transient receptor potential cation channel subfamily V member 1)GPR55 (G protein-coupled receptor 55)FAAH

Beyond the preview

Go deeper on dronabinol + cannabidiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dronabinol + cannabidiol.

Explore the full profile